Gilead Sciences Officer Files Form 144 to Sell 3,000 Shares Under 10b5-1 Plan

Executive Summary

On October 15, 2026, Johanna Mercier, an Officer at Gilead Sciences, Inc. (GILD), filed a Form 144 notifying the proposed sale of 3,000 shares of common stock with an aggregate market value of approximately $468,660.00. The proposed sale is executed through Morgan Stanley Smith Barney LLC pursuant to a Rule 10b5-1 trading plan adopted on February 20, 2025.

Transaction Details

• Security: Common Stock
• Proposed Sale Volume: 3,000 shares
• Aggregate Market Value: $468,660.00 (~$156.22 per share)
• Acquisition Origin: The shares were acquired on February 4, 2025, from the issuer as performance shares.
• Recent Prior Sales: The insider previously sold 3,000 shares on September 15, 2026 ($432,646.20 gross proceeds) and 28,000 shares on August 17, 2026 ($3,853,907.85 gross proceeds).

Market and Trading Context

With 1,239,955,155 shares outstanding, this proposed disposition represents a negligible fraction of the company's total float. Given that the sale is modest in size, follows a pre-established Rule 10b5-1 trading plan adopted months prior, and represents recurring liquidity from vested equity compensation, this filing holds low trading significance for market participants.